A5036063618- Ovarian cancer diagnosis and treatment
- Endometrial and Cervical Cancer Treatments
- Intraperitoneal and Appendiceal Malignancies
- Clinical practice guidelines implementation
- Uterine Myomas and Treatments
- Cancer Diagnosis and Treatment
- Global Healthcare and Medical Tourism
- Management of metastatic bone disease
- Endometriosis Research and Treatment
- Cervical Cancer and HPV Research
- Multiple and Secondary Primary Cancers
- Cancer Risks and Factors
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Viral-associated cancers and disorders
- Renal and Vascular Pathologies
- Cancer survivorship and care
- Colorectal and Anal Carcinomas
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
- Renal cell carcinoma treatment
- BRCA gene mutations in cancer
- Angiogenesis and VEGF in Cancer
- Colorectal Cancer Surgical Treatments
- Renal Diseases and Glomerulopathies
Massachusetts General Hospital
2019-2024
Northwestern University
2017-2024
Harvard University
2019-2024
University of Southern California
2017-2023
Gynecologic Oncology Group
2013-2023
Lemuel Shattuck Hospital
2021
University of Cincinnati
2013-2020
Reproductive Science Center
2019
University of Cincinnati Medical Center
2014-2017
The Ohio State University Wexner Medical Center
2012-2016
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States and country’s fifth most common mortality women. A major challenge treating that patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating ovary, fallopian tube, or peritoneum, as these are all managed a similar manner. Most recommendations based on data with subtypes─high-grade serous grade 2/3 endometrioid. The also include specifically for less cancers,...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations diagnosis, evaluation, treatment, and follow-up ovarian, fallopian tube, primary peritoneal cancers. These Insights summarize panel discussion behind recent important updates to guidelines, including revised guidance on alternative chemotherapy regimens advanced age and/or...
The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations this disease. These Insights detail how the evolution of use PARP inhibitors as maintenance single-agent regimens ovarian cancer informed panel in guidelines.
Uterine serous cancer (USC) comprises around 10% of all uterine cancers. However, USC accounts for approximately 40% deaths, which is attributed to tumor aggressiveness and limited effective treatment. Galectin 3 (Gal3) has been implicated in promoting aggressive features some malignancies. Gal3's role pathology lacking.
Many patients with advanced ovarian cancer will develop recurrent disease. For those who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment platinum monotherapy. However, many clinically relevant neurotoxicity, frequently resulting in discontinuation. The efficacy and safety an alternative regimen that does not show significant neurotoxicity were evaluated by comparing gemcitabine-carboplatin...
Purpose To compare surgeons' operative assessments of residual disease (RD) to those identified on postoperative computed tomography (CT) scans in patients with advanced ovarian carcinoma reported have undergone optimal primary cytoreduction. Patients and Methods All at one two institutions, who were scheduled surgery for presumed cancer, asked consent a CT scan if cytoreduction ≤ 1 cm RD was reported. findings graded using qualitative analysis scale from (normal) 5 (definitely malignant)....